ACAmandine Coffy

Amandine Coffy

*This is an algorithmically generated author record based on publicly available information.

Amandine Coffy has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Benoit You

    Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Hospices Civils of Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921, Oullins, France; GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), France; GINEGEPS (GINEco Group on Early Phase Studies), France; Hospices Civils de Lyon, Lyon, France

    1 shared publication
  • Carole Corsini

    Department of Cancer Genetics, CHU Montpellier, Univ Montpellier, Montpellier, France

    1 shared publication
  • Chloé Rideau

    Department of Cancer Genetics, CHU Montpellier, Université de Montpellier, 34000 Montpellier, France

    1 shared publication
  • Clare Turnbull

    Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK

    1 shared publication
  • David Geneviève

    CHU Montpellier, Centre de Référence Maladies Rares Anomalies du Développement et Syndromes malformatifs, Montpellier, France

    1 shared publication
  • Frédéric Thomas

    CREEC/CANECEV, MIVEGEC (CREES) Department University of Montpellier, CNRS, IRD Montpellier France

    1 shared publication

Latest Publications

  • Open Access

    Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

    by Pascal Pujol, Kevin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daurès, Frédérique Penault Llorca, Frédéric Thomas, Kevin Hughes, Clare Turnbull, et al.

    Background: Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant setting. Therefore, we need to reassess the frequency of gBRCA1 and gBRCA2 in order to redefine the criteria for women and tumor phenotype that should be tested. Objective: We studied the relative distribution of gBRCA1 and gBRCA2 in unselected populations of women with breast cancer and in unaffected individuals. We also analyzed the proportion of estrogen receptor (ER)-positive (ER+) tumors in unselected breast cancer patients with gBRCA. Design: We performed a meta-analysis of studies of unselected breast cancer that analyzed the relative contribution of gBRCA1 versus gBRCA2 among unselected breast cancer cases in gBRCA carriers. We then performed a meta-analysis of gBRCA carriage in unaffected individuals from genome-wide population studies, the gnomAD databank, and case–control studies. Results: The BRCA2 gene was involved in 54% of breast cancer cases in unselected patients with gBRCA (n = 108,699) and 60% of unaffected individuals (n = 238,973) as compared with 38% of the largest gBRCA family cohort (n = 29,700). The meta-analysis showed that 1.66% (95% CI 1.08–2.54) and 1.71% (95% CI 1.33–2.2) of unselected breast cancer patients carried gBRCA1 and gBRCA2, respectively. In a population of unaffected individuals, the frequency of heterozygosity for gBRCA1 and gBRCA2 was estimated at 1/434 and 1/288, respectively. Nearly 0.5% of unaffected individuals in the studied populations carried a gBRCA. Carriage of a gBRCA was 2.5% for patients with ER+ tumors (95% CI 1.5–4.1) and 5.7% (95% CI 5.1–6.2) for those with ER- tumors. Overall, 58% of breast tumors occurring in women carrying a gBRCA were ER+ (n = 86,870). Conclusions: This meta-analysis showed that gBRCA2 carriage is predominant in unselected breast cancer patients and unaffected individuals. ER+ tumors among women with gBRCA-related breast cancer are predominant and have been underestimated. Because PARPi agents improve progression-free survival with ER+ gBRCA breast cancer in most clinical trials, breast cancer should be considered, regardless of ER status, for BRCA1/2 screening for therapeutic purposes.